Pierre Fabre Pharmaceuticals宣布从Atara Biotherapeutics转让Tabelecleucel治疗EB病毒阳性移植后淋巴增生性疾病的生物许可申请

美股速递
Nov 03, 2025

Pierre Fabre Pharmaceuticals宣布,从Atara Biotherapeutics转让Tabelecleucel用于治疗EB病毒阳性移植后淋巴增生性疾病(EBV+ PTLD)的生物许可申请(BLA)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10